Anti-VEGF for polypoidal choroidal vasculopathy improves visual acuity up to 2 years

Three ranibizumab injections and subsequent re-injections improved visual acuity and foveal thickness but did not eliminate branching vascular networks in eyes with polypoidal choroidal vasculopathy, according to a study. Improvements in visual acuity decreased after 1 year.The prospective study included 75 eyes of 73 patients with symptomatic polypoidal choroidal vasculopathy who received one monthly intravitreal 0.5 mg injection of Lucentis (ranibizumab, Genentech) for 3 months and subsequent re-injection on an as-needed basis. Two-year results were analyzed.

Full Story →